Latest Insider Transactions at Merck & Co., Inc. (MRK)
This section provides a real-time view of insider transactions for Merck & Co., Inc. (MRK). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Merck & Co., Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Merck & Co., Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 19
2025
|
Johannes Jacobus Oosthuizen President, U.S. Market |
SELL
Open market or private sale
|
Direct |
8,500
-21.68%
|
$714,000
$84.09 P/Share
|
|
Feb 13
2025
|
David Michael Williams EVP,Chief Info&Digital Officer |
SELL
Open market or private sale
|
Direct |
6,000
-19.92%
|
$510,000
$85.34 P/Share
|
|
Feb 08
2025
|
Johannes Jacobus Oosthuizen President, U.S. Market |
SELL
Payment of exercise price or tax liability
|
Direct |
6,404
-14.04%
|
$557,148
$87.28 P/Share
|
|
Feb 08
2025
|
Johannes Jacobus Oosthuizen President, U.S. Market |
BUY
Exercise of conversion of derivative security
|
Direct |
13,002
+22.18%
|
$1,131,174
$87.28 P/Share
|
|
Feb 06
2025
|
Inge G Thulin Director |
BUY
Open market or private purchase
|
Direct |
2,832
+49.13%
|
$249,216
$88.25 P/Share
|
|
Feb 06
2025
|
Cristal N Downing Chief Comm. & Public Afrs Ofcr |
SELL
Open market or private sale
|
Direct |
2,361
-24.99%
|
$207,768
$88.76 P/Share
|
|
Feb 05
2025
|
Douglas M Baker Jr Director |
BUY
Open market or private purchase
|
Direct |
15,000
+48.39%
|
$1,320,000
$88.5 P/Share
|
|
Jan 27
2025
|
Dalton Smart SVP Fin. - Global Controller |
BUY
Grant, award, or other acquisition
|
Direct |
2,586
+26.94%
|
$250,842
$97.94 P/Share
|
|
Jan 27
2025
|
David Michael Williams EVP,Chief Info&Digital Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,246
+25.38%
|
$993,862
$97.94 P/Share
|
|
Jan 27
2025
|
Jennifer Zachary EVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
25,423
+31.5%
|
$2,466,031
$97.94 P/Share
|
|
Jan 27
2025
|
Caroline Litchfield EVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
23,432
+23.97%
|
$2,272,904
$97.94 P/Share
|
|
Jan 27
2025
|
Johannes Jacobus Oosthuizen President, U.S. Market |
BUY
Grant, award, or other acquisition
|
Direct |
8,664
+20.99%
|
$840,408
$97.94 P/Share
|
|
Jan 27
2025
|
Cristal N Downing Chief Comm. & Public Afrs Ofcr |
BUY
Grant, award, or other acquisition
|
Direct |
9,446
+50.0%
|
$916,262
$97.94 P/Share
|
|
Jan 27
2025
|
Dean Y Li Executive VP & President, MRL |
BUY
Grant, award, or other acquisition
|
Direct |
32,621
+29.07%
|
$3,164,237
$97.94 P/Share
|
|
Jan 27
2025
|
Robert M Davis Chairman, CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
95,275
+17.68%
|
$9,241,675
$97.94 P/Share
|
|
Jan 27
2025
|
Richard R. De Luca EVP&Pres, Merck Animal Heallth |
BUY
Grant, award, or other acquisition
|
Direct |
25,438
+12.44%
|
$2,467,486
$97.94 P/Share
|
|
Jan 27
2025
|
Chirfi Guindo Chief Marketing Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,158
+28.94%
|
$2,731,326
$97.94 P/Share
|
|
Jan 27
2025
|
Sanat Chattopadhyay Exe V-P & Pres. MMD |
BUY
Grant, award, or other acquisition
|
Direct |
28,136
+26.32%
|
$2,729,192
$97.94 P/Share
|
|
Aug 05
2024
|
Chirfi Guindo Chief Marketing Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
17,412
-30.13%
|
$2,002,380
$115.2 P/Share
|
|
Aug 05
2024
|
Chirfi Guindo Chief Marketing Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
36,901
+38.97%
|
$4,243,615
$115.2 P/Share
|
|
May 04
2024
|
Dalton Smart SVP Fin. - Global Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
302
-6.38%
|
$38,354
$127.51 P/Share
|
|
May 04
2024
|
Dalton Smart SVP Fin. - Global Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
612
+11.46%
|
$77,724
$127.51 P/Share
|
|
May 04
2024
|
Michael A Klobuchar EVP - Chief Strategy Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
437
-1.82%
|
$55,499
$127.51 P/Share
|
|
May 04
2024
|
Michael A Klobuchar EVP - Chief Strategy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
887
+3.56%
|
$112,649
$127.51 P/Share
|
|
May 04
2024
|
Richard R. De Luca EVP&Pres, Merck Animal Heallth |
SELL
Payment of exercise price or tax liability
|
Direct |
13,360
-8.16%
|
$1,696,720
$127.51 P/Share
|
|
May 04
2024
|
Richard R. De Luca EVP&Pres, Merck Animal Heallth |
BUY
Exercise of conversion of derivative security
|
Direct |
27,126
+14.21%
|
$3,445,002
$127.51 P/Share
|
|
May 04
2024
|
Johannes Jacobus Oosthuizen President, U.S. Market |
SELL
Payment of exercise price or tax liability
|
Direct |
450
-1.85%
|
$57,150
$127.51 P/Share
|
|
May 04
2024
|
Johannes Jacobus Oosthuizen President, U.S. Market |
BUY
Exercise of conversion of derivative security
|
Direct |
912
+3.62%
|
$115,824
$127.51 P/Share
|
|
May 03
2024
|
Dalton Smart SVP Fin. - Global Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
845
-9.98%
|
$108,160
$128.26 P/Share
|
|
May 03
2024
|
Dalton Smart SVP Fin. - Global Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
2,046
+18.8%
|
$261,888
$128.26 P/Share
|
|
May 02
2024
|
Joseph Romanelli President, Human Health Int?l |
SELL
Payment of exercise price or tax liability
|
Direct |
1,115
-5.11%
|
$142,720
$128.8 P/Share
|
|
May 02
2024
|
Joseph Romanelli President, Human Health Int?l |
BUY
Exercise of conversion of derivative security
|
Direct |
2,262
+9.39%
|
$289,536
$128.8 P/Share
|
|
May 02
2024
|
Dalton Smart SVP Fin. - Global Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
131
-4.3%
|
$16,768
$128.8 P/Share
|
|
May 02
2024
|
Dalton Smart SVP Fin. - Global Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
381
+11.11%
|
$48,768
$128.8 P/Share
|
|
Feb 14
2024
|
Robert M Davis Chairman, CEO & President |
SELL
Open market or private sale
|
Direct |
85,021
-19.62%
|
$10,627,625
$125.4 P/Share
|
|
Feb 14
2024
|
Robert M Davis Chairman, CEO & President |
BUY
Exercise of conversion of derivative security
|
Direct |
85,021
+16.4%
|
$6,206,533
$73.73 P/Share
|
|
Feb 14
2024
|
Caroline Litchfield EVP & CFO |
SELL
Open market or private sale
|
Direct |
38,291
-42.93%
|
$4,786,375
$125.5 P/Share
|
|
Feb 14
2024
|
Caroline Litchfield EVP & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
38,291
+30.03%
|
$2,220,878
$58.08 P/Share
|
|
Feb 13
2024
|
Robert M Davis Chairman, CEO & President |
SELL
Open market or private sale
|
Direct |
150,000
-15.9%
|
$18,900,000
$126.06 P/Share
|
|
Feb 13
2024
|
Robert M Davis Chairman, CEO & President |
BUY
Exercise of conversion of derivative security
|
Direct |
150,000
+13.75%
|
$11,100,000
$74.55 P/Share
|
|
Feb 13
2024
|
Joseph Romanelli President, Human Health Int?l |
SELL
Open market or private sale
|
Direct |
1,000
-4.86%
|
$124,000
$124.89 P/Share
|
|
Feb 09
2024
|
Dean Y Li Executive VP & President, MRL |
SELL
Open market or private sale
|
Direct |
14,702
-24.12%
|
$1,837,750
$125.5 P/Share
|
|
Feb 09
2024
|
Dean Y Li Executive VP & President, MRL |
BUY
Exercise of conversion of derivative security
|
Direct |
14,702
+19.44%
|
$911,524
$62.07 P/Share
|
|
Feb 07
2024
|
David Michael Williams EVP,Chief Info&Digital Officer |
SELL
Open market or private sale
|
Direct |
1,451
-6.82%
|
$184,277
$127.57 P/Share
|
|
Feb 02
2024
|
Johannes Jacobus Oosthuizen President, U.S. Market |
SELL
Open market or private sale
|
Direct |
18,959
-44.84%
|
$2,407,793
$127.17 P/Share
|
|
Feb 02
2024
|
Johannes Jacobus Oosthuizen President, U.S. Market |
BUY
Exercise of conversion of derivative security
|
Direct |
20,937
+16.84%
|
$1,633,086
$78.73 P/Share
|
|
Feb 02
2024
|
Jennifer Zachary EVP, General Counsel |
SELL
Open market or private sale
|
Direct |
49,499
-63.01%
|
$6,236,874
$126.97 P/Share
|
|
Feb 02
2024
|
Jennifer Zachary EVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
19,417
+19.82%
|
$1,689,279
$87.1 P/Share
|
|
Feb 02
2024
|
Steven Mizell EVP, Chief HR Officer |
SELL
Open market or private sale
|
Direct |
50,694
-68.22%
|
$6,387,444
$126.65 P/Share
|
|
Feb 02
2024
|
Steven Mizell EVP, Chief HR Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
32,994
+16.06%
|
$2,375,568
$72.22 P/Share
|